Polymeric lamellar substrate particles for intranasal vaccination

Advanced Drug Delivery Reviews

Volumn 51, Issue 1-3, 2001, Pages 97-111

  Jabbal Gill, Inderjit ^a   Lin, Wu ^a   Kistner, Otfried ^b   Davis, Stanley S ^a   Illum, Lisbeth ^a  

^a Drug Delivery and Clinical Research Centre Ltd   (United Kingdom)

^b BAXTER INNOVATIONS GMBH   (Austria)

Author keywords

Adjuvants; Mucosal; Nasal; PLSP; Polylactide; Vaccine

Indexed keywords

ADSORPTION; ANTIGENS; IMMUNIZATION; PH EFFECTS; POLYMERS; PRECIPITATION (CHEMICAL); SHEAR STRESS;

VIRAL VACCINES;

VACCINES;

POLYGLACTIN; POLYLACTIDE; POLYMER;

ACIDITY; ADSORPTION; BIODEGRADATION; CONTROLLED DRUG RELEASE; DRUG DELIVERY SYSTEM; ENCAPSULATION; HUMAN; IMMUNOGENICITY; MUCOSAL IMMUNITY; NONHUMAN; PRECIPITATION; PRIORITY JOURNAL; REVIEW; SHEAR STRESS;

ADMINISTRATION, INTRANASAL; ADSORPTION; ANIMALS; HUMANS; IMMUNITY, MUCOSAL; POLYESTERS; VACCINATION; VACCINES;

EID: 0035940304     PISSN: 0169409X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0169-409X(01)00173-9     Document Type: Review

References (60)

1. Adjuvants for human vaccines - Current status, problems and future prospects - Review
2. ISCOMs and immunostimulation with viral antigens
3. Critical appraisal of emulsified oil adjuvants applied to viral vaccines
4. Sensitization and antibody formation after injection of tubercle bacilli and paraffin oil
5. Immune responses to epitopes inserted in Salmonella flagelin
6. Similar subclass antibody responses after intranasal immunization with UV-inactivated RSV mixed with cholera toxin or live RSV
7. Protection against influenza virus infection by vaccine inoculated intranasally with cholera toxin B subunit
8. Immunogenicity and protection in small animal models with controlled release tetanus toxoid microparticles as a single-dose vaccine
9. Immunogenicity of single-dose diphtheria vaccines based on PLS/PLGA microspheres in guinea pigs
10. Synthetic oligodeoxynucleotides containing CpG motifs enhance immunogenicity of a peptide malaria vaccine on Aotus monkeys
11. Stimulation of mucosal and systemic antibody responses against Bordetella pertussis filamentous haemagglutinin and recombinant pertussis toxin after nasal administration with chitosan in mice
12. A mucosally delivered vaccine against diphtheria: Formulation of cross reacting material (CRM197) of diphtheria toxin with chitosan enhances local and systemic antibody and Th2 responses following nasal delivery
13. Aluminium is put on trial as a vaccine booster
14. Adjuvant properties of aluminium and calcium compounds
15. Recent advances in mucosal vaccine development
16. Nasal lymphoid tissue, intranasal immunization and compartmentalization of the common mucosal immune system
17. Design and delivery of non-parenteral vaccines
18. Mucosal immunoadjuvant activity of liposomes: Induction of systemic IgG and secretory IgA responses in mice by intranasal immunization with an influenza subunit vaccine and coadministered liposomes
19. Safety of a trivalent live attenuated intranasal influenza vaccine, FluMist™, administered in addition to parenteral trivalent inactivated influenza vaccine to seniors with chronic medical conditions
20. Evaluation of trivalent, live, cold-adapted (CAIV-T) and inactivated (TIV) influenza vaccines in prevention of virus infection and illness following challenge of adults with wild-type influenza A (H1N1), A (H3N2) and B viruses
21. Immune responses and protection against Bordetella pertussis infection after intranasal immunization of mice with filamentous haemagglutinin in solution or incorporated in biodegradable microparticles
22. Physicochemical and immunological studies on the stability of free and microsphere-encapsulated tetanus toxoid in vitro
23. Resorbable lamellar particles of polylactide as adjuvants for influenza virus vaccines
24. Induction of cellular immunity to mycobacterial antigen adsorbed on lamellar particles of lactide polymers
25. The immune responses following nasal and intra muscular administration of tetanus toxoid adsorbed on PLA lamellae
26. Potential of polymeric lamellar substrate particles (PLSP) as adjuvants for vaccines
27. Preparation of polymeric lamellar substrate particles of specific size ranges as potential vaccine adjuvants
28. Biodegradable and biocompatibility of PLA and PLGA microparticles
29. Enzymatic activity toward poly(l-lactic acid) implants
30. Biodegradation of aliphatic polyesters
31. Hydrolytic degradation of devices based on poly(DL-lactic acid) size dependence
32. In vitro and in vivo degradation of poly(DL-lactide/glycolide) type microspheres made by solvent method
33. Biodegradable polymers for use in surgery - Poly(glycolic)/poly(lactic acid) home and copolymers. 2. In vitro degradation
34. Degradation of poly (D,L-lactic acid) microspheres: Effect of molecular weight
35. Ambiguities in the preclinical quality assessment of microparticle vaccine. Review
36. Protein absorption to polymer particles: Role of surface properties
37. Adsorption of γ-globulin, a model protein for antibody, on colloidal particles
38. B-Cell memory is short lived in the absence of antigen
39. Parameters affecting the immunogenicity of microencapsulated tetanus toxoid
40. Adjuvants: Current status, clinical perspectives and future prospects
41. Cytokine regulation of humoral responses
42. Assembly and intracellular transport of major histocompatibility complex molecules
43. Delivery of protein antigen to the major histocompatibility complex Class I-restricted antigen presentation pathway
44. The selective induction of different immune responses by vaccine adjuvant
45. Adjuvants - A balance between toxicity and adjuvanticity
46. Long-lived cytotoxic T lymphocyte memory in mucosal tissues after mucosal but not systemic immunization
47. Cytotoxic T cells in small intestine epithelial lamina propria and lung lymphocytes
48. Leukocytes in the intestinal epithelium: An unusual immunological compartment
49. Regional specialization in the mucosal immune system: Primed cells do not always home along the same track. Review
50. Rapid recovery of lung histology correlates with clearance on influenza virus by specific CD8 + cytotoxic T cells
51. Characterization and in vivo distribution of influenza-virus-specific-lymphocytes in the murine respiratory tract
52. T lymphocytes in the genital lymph nodes protect mice from intravaginal infection with herpes simplex virus type 2
53. The long-term maintenance of cytotoxic T cell memory does not require persistence antigen
54. T cell memory is short-lived in the absence of antigen
55. Antivirally protective cytotoxic T cell memory to lymphocytic choriomeningitis virus is governed by persisting antigen
56. Cross-reactivities in memory cytotoxic lymphocyte recognition of heterologous viruses
57. Biodegradable lamellar particles of poly(lactide) induce sustained immune response to a single dose of adsorbed protein
58. Development of a mammalian cell (Vero) derived candidate influenza virus vaccine
59. A novel mammalian cell (Vero) derived influenza vaccine: Development, characterization and industrial scale production